GlassScriptPhysician profile
Nicholas Inverso
NPI 1396704086
$567.79
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $212 · 2021: $19.87 · 2022: $19.95 · 2023: $69.61 · 2024: $37.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $250.35 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $55.89 | 2019-2024 | Rebyota |
| Abbvie INC. | $42.01 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.67 | 2019 | |
| Echosens North America, INC. | $39.21 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.23 | 2023 | Xifaxan |
| Janssen Biotech, INC. | $20.34 | 2023 | Stelara, Remicade, Simponi Aria |
| Ucb, INC. | $20.32 | 2020 | |
| Boston Scientific Corporation | $19.87 | 2021 | |
| Gilead Sciences, INC. | $16.86 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.04 | 2023 | Dupixent |
| Braintree Laboratories, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Inverso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.